2024
Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapy
2013
Standardized criteria for required palliative care consultation on the solid tumor oncology service.
Adelson K, Paris J, Smith C, Horton J, Morrison R. Standardized criteria for required palliative care consultation on the solid tumor oncology service. Journal Of Clinical Oncology 2013, 31: 37-37. DOI: 10.1200/jco.2013.31.31_suppl.37.Peer-Reviewed Original ResearchPalliative care consultationPalliative careReadmission ratesHospice utilizationASCO guidelinesPC consultationCare consultationsMortality indexStandardized criteriaComparing group 1Improved symptom controlPalliative care consultStage IV diseaseHigh symptom burdenHealth care resourcesCare consultUncontrolled symptomsHospital deathST patientsSymptom controlSymptom burdenDays hospitalizationPrimary outcomeAdvanced cancerStay index